Activist pressure mounts on Mattel as Ariel Investments pushes for sale; DeepValue stays cautious with WAIT rating

What happened

On October 5, 2026, Ariel Investments, holding 5.4% of Mattel, publicly urged the company to consider a sale, stating shares are significantly undervalued under the current structure. This activist pressure arrives amid a challenging operating environment: Mattel's Q3 2025 net sales fell 6% with North America down 12%, gross margin compressed to 50.2% due to tariffs and inflation, and the company's stock has recovered from April lows but remains below its 52-week high. Our DeepValue report currently rates MAT a WAIT, with a base case implied value of $22 and a bear case of $17, noting that at $20.89 the stock already prices in mid-cycle earnings and low-single-digit revenue growth. While Ariel's call for a sale could trigger strategic review and near-term price appreciation, the fundamental issues of retailer ordering shifts, promotional pressure, and tariff exposure remain unresolved. Therefore, we maintain our conservative stance, viewing any sale process as a speculative catalyst that does not alter our fundamental valuation until operational improvements are evident.

Implication

Ariel's stake and statements may force Mattel's board to explore strategic alternatives, which could include a sale to a private equity firm or strategic buyer, potentially unlocking value above the current market price. However, historical precedents show that activist campaigns in consumer staples often lead to cost cuts or divestitures rather than outright sales, and Mattel's brand portfolio might be challenging to sell at a premium given its recent revenue declines. Our analysis indicates that the stock's current valuation at ~15.6x trailing EPS and ~8.8x EV/EBITDA already reflects a recovery scenario, leaving limited margin of safety for new buyers at these levels. The company's operational challenges—North America sales decline, margin compression, and inventory buildup—are likely to persist in the near term, regardless of any sale process, and could pressure earnings further. We recommend investors wait for either a confirmed strategic transaction at a significant premium or a fundamental improvement in operating metrics before increasing exposure, with our preferred entry point remaining around $18.

Thesis delta

The activist campaign introduces a new potential catalyst—a sale process—that could lead to above-market offers and short-term price appreciation. However, this does not change our core thesis: the business remains under pressure from tariffs, promotions, and North America weakness, and at $20.89 the risk-reward is not compelling. We maintain our WAIT rating and $18 attractive entry, while monitoring whether pressure triggers real strategic action.